Highly promising results have been achieved using new agents dedicated to this group of patients, including lomitapide (Lojuxta) [289] available in doses from 5 to 60 mg, mipomersen (Kynamro, which was not authorised for use by the EMA in 2013), as well as new therapies, including, above all, evinacumab (Evkeeza) (Section 9.10), which since June 2021, following a positive decision of the EMA, have been authorised for use in patients with HoFH in the European Union
developmental and nutritional disorders in young animals due to rearing disease, and (secondary) ketosis in cows)
Semaglutide (Ozempic) is a GLP-1 medication designed to support weight loss by reducing appetite, controlling cravings, and promoting sustainable fat loss
Learn about GHK-Cu Topical Serum Application technique matters more than people think: Clean, dry skin